Gyre Therapeutics (GYRE) Revenue (2010 - 2026)
Gyre Therapeutics (GYRE) reported Revenue of $22.5 million for Q1 2026, up 2.09% year-over-year from $22.1 million in Q1 2025, and down 39.46% on a QoQ basis from $37.2 million in Q4 2025.
Gyre Therapeutics (GYRE) has 16 years of Revenue data on file, last reported at $22.5 million in Q1 2026.
- Quarterly Revenue rose 2.09% year-over-year to $22.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $117.0 million (up 16.3% YoY) and the FY2025 annual result came in at $116.6 million, up 10.24% from the prior year.
- Revenue fell to $22.5 million in Q1 2026 per GYRE's latest filing, from $37.2 million in the prior quarter.
- Across five years, Revenue topped out at $101.5 million in Q4 2022 and bottomed at $794000.0 in Q1 2022.
- The 5-year median for Revenue is $27.1 million (2023), against an average of $30.7 million.
- The widest annual swing landed in 2022, when Revenue jumped 4059.67%; it then plunged 73.25% in 2023.
- Tracing GYRE's Revenue over 5 years: stood at $101.5 million in 2022, then sank by 73.25% to $27.1 million in 2023, then increased by 2.67% to $27.9 million in 2024, then soared by 33.45% to $37.2 million in 2025, then slumped by 39.46% to $22.5 million in 2026.
- Per Business Quant, the three latest GYRE Revenue figures stand at $22.5 million (Q1 2026), $37.2 million (Q4 2025), and $30.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 22.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.52 Mn |
| Dec 31, 2025 | 37.20 Mn |
| Sep 30, 2025 | 30.56 Mn |
| Jun 30, 2025 | 26.77 Mn |
| Mar 31, 2025 | 22.06 Mn |
| Dec 31, 2024 | 27.87 Mn |
| Sep 30, 2024 | 25.49 Mn |
| Jun 30, 2024 | 25.23 Mn |
| Mar 31, 2024 | 27.17 Mn |
| Dec 31, 2023 | 27.15 Mn |
| Sep 30, 2023 | 32.04 Mn |
| Jun 30, 2023 | 29.33 Mn |
| Mar 31, 2023 | 24.93 Mn |
| Dec 31, 2022 | 101.50 Mn |
| Mar 31, 2022 | 794,000.00 |
| Dec 31, 2021 | 2.44 Mn |
| Sep 30, 2021 | 2.30 Mn |
| Jun 30, 2021 | 1.13 Mn |
| Mar 31, 2021 | 1.47 Mn |
| Dec 31, 2020 | 2.03 Mn |
| Sep 30, 2020 | 893,000.00 |
| Jun 30, 2020 | 1.66 Mn |
| Mar 31, 2020 | 16.37 Mn |
| Mar 31, 2018 | 6,000.00 |
| Dec 31, 2017 | 318,000.00 |
| Sep 30, 2017 | 318,000.00 |
| Jun 30, 2017 | 111,000.00 |
| Mar 31, 2017 | 271,000.00 |
| Dec 31, 2016 | 71,000.00 |
| Sep 30, 2016 | 109,000.00 |
| Jun 30, 2016 | 109,000.00 |
| Mar 31, 2016 | 109,000.00 |
| Dec 31, 2015 | 109,000.00 |
| Sep 30, 2015 | 109,000.00 |
| Jun 30, 2015 | 859,000.00 |
| Mar 31, 2015 | 672,000.00 |
| Dec 31, 2014 | 672,000.00 |
| Sep 30, 2014 | 547,000.00 |
| Jun 30, 2014 | 297,000.00 |
| Mar 31, 2014 | 297,000.00 |
| Dec 31, 2013 | 93,000.00 |
| Mar 31, 2013 | 3.54 Mn |
| Dec 31, 2012 | 590,000.00 |
| Sep 30, 2012 | 768,000.00 |
| Jun 30, 2012 | 33.65 Mn |
| Mar 31, 2012 | 22.86 Mn |
| Dec 31, 2011 | 18.95 Mn |
| Sep 30, 2011 | 18.96 Mn |
| Jun 30, 2011 | 20.74 Mn |
| Mar 31, 2011 | 38.99 Mn |
| Dec 31, 2010 | 21.93 Mn |
| Sep 30, 2010 | 136,000.00 |
| Jun 30, 2010 | 198,000.00 |